Investigation of Metabolism and Pharmacokinetics and Absolute Bioavailability of BI 685509 (C-14) After Intravenous and Oral Administration in Healthy Male Subjects
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Avenciguat (Primary) ; Avenciguat (Primary)
- Indications Diabetic nephropathies; Portal hypertension; Renal failure
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 25 Nov 2022 Status changed from active, no longer recruiting to completed.
- 04 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2022 Status changed from not yet recruiting to recruiting.